Gilead swings to a big loss on acquisition expense, stock falls after earnings and revenue miss

Shares of Gilead Sciences Inc. fell more than 1% in after-hours trading Thursday after the drugmaker reported that it swung to a large loss during the second quarter and missed estimates even after adjusting for an acquisition.